Мирапекс ПД

Quick links

Choose a section

Quick links to important sections

Advertisements

Мирапекс ПД

Advertisements
Advertisements
Advertisements

Overview of Мирапекс ПД

What is Mirapex PD? (Мирапекс ПД)

Property Description
Active ingredient Pramipexole (Прамипексол)
Form Extended-release tablet (Таблетка с пролонгированным высвобождением)
Pharmacological class Non-ergot Dopamine Agonist (Неэрголиновый агонист дофамина)
Common use Modulation of movement control symptoms (Управление симптомами нарушений движения)
Origin Synthetic (Синтетический)

Mirapex PD is a prescription-only medicine containing the active ingredient pramipexole (INN). It is classified as a non-ergot dopamine agonist, a category of synthetic compounds clinically recognized for their ability to affect chemical signaling in the central nervous system. This specific designation is an important feature, confirming its structure is distinct from older, ergot-derived agents. The product is a single-ingredient product, focusing exclusively on the action of pramipexole dihydrochloride monohydrate.

Unique Form and Action

The distinguishing feature of Mirapex PD is its 'PD' or extended-release delivery system, which means the oral tablet is designed to release pramipexole slowly and continuously over approximately 24 hours. This controlled action is engineered to provide stable therapeutic levels throughout the day. The core mechanism is agonism, where pramipexole binds to dopamine receptors to mimic the body's natural dopamine signals. This action is generally utilized to help improve movement fluidity and reduce difficulties such as involuntary resting movements or stiffness, by restoring crucial chemical signals required for balanced motor function.

Advertisements

What side effects are possible with Мирапекс ПД?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Mirapexin PD (pramipexole) as categorized by government regulatory bodies.

Frequency-Classified Adverse Reactions

The following are classified based on the frequency reported in clinical data:

Classification Examples of Documented Reactions
Very Common (ge 1/10) Somnolence (Drowsiness), Nausea, Dyskinesia
Common (ge 1/100 to < 1/10) Hallucinations, Insomnia, Dizziness, Vomiting, Constipation, Orthostatic Hypotension, Peripheral Edema
Uncommon (ge 1/1,000 to < 1/100) Impulse Control Disorders (e.g., pathological gambling, hypersexuality), Sudden onset of sleep, Confusion, Cardiac failure, Decreased libido

Serious Safety Considerations

The official safety profile highlights several serious risks, including sudden onset of sleep without warning, severe disturbances like psychotic disorders (e.g., hallucinations, confusion, delusion), and the development of various impulse control disorders. A rare but serious documented risk is Rhabdomyolysis (severe muscle breakdown).

Safety Limitations and Monitoring

Orthostatic Hypotension (a drop in blood pressure upon standing) is a common adverse reaction, particularly at the start of treatment or following dose increases, and caution is required for patients with pre-existing cardiovascular conditions. The drug's clearance is reliant on kidney function; therefore, the dosage must be adjusted in patients with renal impairment to prevent excessive accumulation and potential toxicity, a measure mandated by regulatory guidelines.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for pramipexole, the active ingredient in Мирапекс ПД, states there is no clinical experience with significant overdosage. Due to the nature of the drug and the necessary management steps, immediate medical attention is required upon any suspicion of overdose or accidental high-dose exposure.

Documented Overdose Manifestations

The manifestations of overdose are based on very limited clinical data. Officially documented signs from a case of high-dose exposure included a rapid pulse, specifically tachycardia (pulse rate increased to between 100 and 120 beats/minute), while blood pressure remained stable. A recognized, potential severe effect listed in the regulatory profile is the development of signs of Central Nervous System (CNS) stimulation.

Emergency Management Directives

Official labeling states there is no known antidote for overdosage involving a dopamine agonist. Management must therefore be symptomatic and supportive, involving specific medical procedures:

  • General supportive measures and administration of intravenous fluids.
  • Gastric lavage may be required as part of the initial management.
  • Continuous Electrocardiogram (ECG) monitoring is required to assess and manage cardiac status.
  • For severe manifestations such as CNS stimulation, the use of a phenothiazine or other butyrophenone neuroleptic agent may be indicated under direct medical supervision.
Advertisements

Therapeutic Uses of Мирапекс ПД

What Мирапекс ПД treats: Main Uses and Benefits

Mirapex PD (pramipexole extended-release) is a specialized prescription medication used to provide continuous, symptomatic relief across the clinical manifestations of Idiopathic Parkinson's Disease (PD). The medication is considered relevant for the management of the signs and symptoms of PD.

This medication is commonly used to help with the core motor symptoms, including involuntary tremor (shaking at rest), muscle rigidity (stiffness), and profound bradykinesia (slowed movements). In clinical settings, it is applied during phases where symptoms become more noticeable, both as an initial monotherapy and as part of combination therapy for established disease marked by motor fluctuations.

The benefit of the extended-release formulation is that it may assist with maintaining supportive relief throughout the day, which helps patients cope more steadily with difficult episodes. Furthermore, it plays a role in managing associated non-motor disturbances; specifically, it can help ease the burden of PD-related depressive symptoms and anhedonia.


Quick Fact: Relief for Motor and Non-Motor Symptoms

Mirapex PD is applied across therapeutic domains involving certain distressing symptoms that create noticeable physiological strain, supporting the management of both the primary movement difficulties and specific mood disturbances associated with the condition.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Мирапекс ПД (Pramipexole Extended-Release)

This section summarizes the patient populations defined in official regulatory documents as eligible or restricted for the use of Мирапекс ПД (pramipexole extended-release).

Population Status Constraint or Exclusion
Must Not Use (Contraindicated) Individuals with known hypersensitivity (allergy) to pramipexole or any of the product's inactive ingredients.
Not Recommended Children and adolescents under 18 years of age; safety and effectiveness have not been established in the pediatric population.
Use Restricted/Limited Patients with moderate renal impairment (creatinine clearance between 30 and 50 mL/min) require caution and an initial reduced dosing frequency.
Not Recommended Patients with severe renal impairment (creatinine clearance below 30 mL/min) or those undergoing hemodialysis, as the drug has not been adequately studied in this group.
Use Restricted/Limited Pregnant women: Use is only recommended if the potential benefit justifies the potential risk. Lactating women: Use is not recommended, as pramipexole may suppress lactation and excretion into human milk is not fully known.

Only adults with the indicated condition (Parkinson's disease) are officially within the scope of authorized use. The extended-release formulation is not authorized for use in other indications, such as Restless Legs Syndrome.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for pramipexole (the active ingredient in Мирапекс ПД) defines a specific set of documented interactions primarily based on its renal clearance pathway and dopamine agonist activity.

Clinically relevant interactions mediated by Cytochrome P450 (CYP) enzymes are generally not expected, as pramipexole has low metabolic elimination.

Documented Pharmacokinetic Interactions

Pramipexole is eliminated mainly by renal tubular secretion via the cationic transport system. Substances that compete for this transport mechanism can reduce pramipexole clearance and increase its plasma exposure.

Interacting Substance Official Interaction Outcome
Cimetidine Inhibits renal secretion, increasing pramipexole plasma exposure ( AUC and C max) by approximately 50%.
Amantadine Potential for reduced clearance due to competition for the common renal transport system.

Documented Pharmacodynamic Interactions

Interacting Substance/Class Official Interaction Outcome
Dopamine Antagonists May diminish the efficacy of pramipexole's therapeutic effect. Co-administration is generally restricted.
Levodopa Leads to potentiation of levodopa effects, requiring a mandated dose reduction for Levodopa.
Alcohol / Sedating Drugs Increased risk of somnolence due to documented additive CNS effects.

Other Constraints

Food does not affect the total extent of absorption ( AUC) of the extended-release tablet. Furthermore, the impact of clearance-related interactions is heightened in patients with renal impairment due to their already reduced baseline pramipexole clearance.

Advertisements

Mechanism of Action

Dopamine Receptor Agonism

Мирапекс ПД (pramipexole) exerts its effect through the Central Nervous System (CNS) by acting as a dopamine receptor agonist. The active ingredient binds directly to and activates postsynaptic D2 and D3 dopamine receptor subtypes, primarily within the striatum. This interaction mimics the function of endogenous dopamine, initiating signaling cascades that modulate dopaminergic activity in key brain regions .


Pathway and Physiological Modulation

This activity is focused on modulating signaling within the nigrostriatal pathway and other circuits of the basal ganglia. The targeted central action helps modulate the complex neuronal output associated with motor control. The ПД (extended-release) formulation is designed to release pramipexole gradually, resulting in the tonic modulation of motor pathways by maintaining a stable profile of receptor activation. This overall mechanism leads to the physiological consequence of altered motor circuit signaling and modulation of skeletal muscle output.

Advertisements

Dosage and Administration Information

How to Use Мирапекс ПД: Official Administration Guidelines

Мирапекс ПД (pramipexole extended-release) is administered via the oral route as a once-daily extended-release tablet. The official usage guidelines emphasize a strict administration process to ensure the medication functions as intended.

Administration and Dosing Structure

The treatment protocol is initiated with a low starting dose that is subsequently adjusted through a gradual titration process. The standard starting dose is 0.375 mg once daily. The dose should be increased slowly, in increments of 0.375 mg or 0.75 mg, and adjustments should not occur more frequently than every five to seven days. The maximum recommended daily dose for this formulation is 4.5 mg. The tablet may be taken with or without food at the same time each day.

Procedural Requirement Official Instruction
Tablet Handling The extended-release tablet must be swallowed whole and must not be chewed, crushed, or divided.
Frequency Taken once daily.
Missed Dose If a dose is missed by more than 12 hours, it should be skipped, and the next dose taken at the usual time; doubling the dose is strictly prohibited.

Population-Specific Dosing

Dosing requires adjustment for patients with impaired kidney function. For those with moderate renal impairment (Creatinine Clearance 30–50 mL/min), the starting dose is modified to 0.375 mg every other day, and the maximum dose is restricted to 2.25 mg per day. Conversely, no specific dose adjustment is necessary for hepatic impairment.

Treatment discontinuation must also be procedural: a gradual tapering of the daily dose is required to cease medication use, rather than abrupt cessation.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Мирапекс ПД

Evidence for Managing Motor Symptoms in Early Parkinson's Disease

Research explored how symptoms change over time in Parkinson's disease, which is a condition marked by functional limitations. The core evidence comes from short-term, randomized controlled trials (RCTs) comparing the extended-release (ER) medication to a placebo. These studies monitored outcomes reflecting daily functioning or activity level in adults with early-stage PD, including studies that examined switching patients from the immediate-release (IR) tablet. Findings describe patterns observed in these studies, where data show patterns related to how symptoms evolved in the observed populations. Evidence is limited because the controlled, blinded studies were generally conducted over an intermediate duration, with follow-up durations that were limited to less than one year.

Evidence for Adjunctive Use in Advanced Parkinson's Disease

Studies monitored outcomes reflecting daily functioning or activity level in individuals with advanced PD who were already taking levodopa and experiencing motor fluctuations. Research examined changes in the amount of daily time patients spent in an "off" state, an outcome capturing phases of heightened symptom activity. Trials reported measurements of the change in daily "off" time relative to placebo across the study population. Certainty remains low regarding direct, long-term comparative evidence against other adjunctive therapies, and long-term effects are not fully established based on extended, blinded clinical trials.

Research on Associated Non-Motor Symptoms (Mood and Quality of Life)

The evidence base for non-motor symptoms was studied for outcomes related to systemic or functional imbalance, such as mood disturbances. Research explored short-term symptom changes, using standardized scales to measure patient-reported outcomes describing perceived discomfort. Findings were mixed when comparing measured changes across the body of synthesized evidence. Evidence quality varies across studies, and the variability of findings means that the effect on mood issues is not fully established.

What Is Still Uncertain About Мирапекс ПД

The long-term effects are not fully established regarding sustained outcomes, as there is limited information for effectiveness observed under double-blind, randomized conditions beyond an intermediate timeframe. Comparative evidence is lacking for a direct, long-term trial against other similar types of medication. Furthermore, subgroup findings are uncertain for certain populations, such as very elderly patients, as sample sizes were modest in these specific areas.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Мирапекс ПД (FAQ)

Q: Is Mirapex PD authorized only for Parkinson’s disease?

Official product information states that the extended-release formulation (Мирапекс ПД) is authorized for the treatment of Parkinson's disease. While the immediate-release version is authorized for moderate to severe restless legs syndrome (RLS) in some regions, the extended-release form is not considered suitable for RLS.

Q: What is the main difference between Mirapex PD and regular Mirapex?

The primary difference lies in the release mechanism and dosing frequency. Мирапекс ПД (extended-release) is designed to release the active ingredient slowly over 24 hours and the dosing frequency is described as once daily. The regular immediate-release tablet is typically taken multiple times a day. Official administration guidelines state the extended-release tablet must be swallowed whole and should not be divided or crushed.

Q: Are there long-term side effects described in studies?

Studies, including long-term open-label extensions lasting nearly two years, examined the safety profile of the medication. The evidence indicates that the reported adverse reactions were generally consistent with those expected for this class of medication. No new or unexpected long-term safety signals were identified compared to the immediate-release formulation.

Q: Is Mirapex PD used in elderly patients?

The medication is approved for use in adults, which includes the elderly population. However, official safety information notes that certain adverse reactions, such as confusion and hallucinations, may increase in frequency with age.

Q: How does Mirapex PD affect the ability to drive vehicles?

Regulatory documents contain specific warnings regarding driving and operating machinery. Due to the risk of somnolence (drowsiness) and sudden onset of sleep without warning, regulatory guidance advises against driving or engaging in potentially dangerous activities until the patient knows how the medication affects them.

Q: Does this drug affect mood or emotions?

The official safety profile includes potential effects on mood, cognition, and behavior. Documented reactions include confusion, hallucinations, and a decrease in libido. Impulse control disorders, such as pathological gambling or hypersexuality, are also listed as uncommon adverse reactions.

Q: Can the side effects of the drug disappear over time?

Official regulatory information suggests that certain transient side effects are more likely to occur early in the course of treatment. This includes issues like dizziness and orthostatic hypotension (a drop in blood pressure when standing up). For some of these initial symptoms, evidence indicates they may lessen over time.

Q: Can taking Mirapex PD affect the nature of dreams?

Yes, official safety information lists abnormal dreams as a possible adverse reaction. This is generally noted as a less common effect in the product's safety profile.

Q: How quickly do patients usually start to feel the effect of Mirapex PD, and when can a difference be noticed?

Clinical studies tracked objective symptom changes compared to a placebo. Evidence indicates that a statistically significant difference in symptom reduction was observed after approximately three weeks of dose titration, during the period of dose adjustment (titration).

Q: Is this a medicine that needs to be taken constantly?

As the medication is utilized for the symptomatic management of Parkinson's disease, which is a progressive and chronic condition, treatment is typically continuous. Official guidelines describe that medication use should cease via a gradual dose tapering process, as abrupt discontinuation is not recommended.

Q: Are any tests required before starting Mirapex PD?

Official regulatory documents indicate that an assessment of kidney function (renal clearance) is necessary before beginning treatment. This assessment is required because the dosage must be adjusted in patients who have renal impairment to prevent drug accumulation.

Q: What to do for nausea related to the drug (general information)?

Nausea is listed as a very common side effect. Official prescribing information notes that administering the extended-release tablet with food may help to reduce the occurrence of nausea, without affecting the overall absorption of the active ingredient.

Q: Why do some people say they feel 'better' on this drug?

Clinical studies report objective measures related to effectiveness, focusing on changes in functional outcomes. These studies showed a significant reduction in the severity of motor symptoms associated with Parkinson's disease, such as difficulties with daily living activities, compared to placebo.

Advertisements

How should Мирапекс ПД be stored and disposed of?

Official Storage and Disposal Instructions for Mirapex PD (Pramipexole Extended-Release Tablets)

Mirapex PD must be stored at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F), with permitted brief excursions. The medication must be kept away from excess heat and moisture, and it is required that the product not be frozen and be protected from light.

Packaging and Safety

The tablets must be stored in the original container and kept tightly closed to maintain integrity. For safety, it is mandatory to keep Mirapex PD and all medicines out of the sight and reach of children.

Disposal

Do not keep outdated or unneeded medicine. Official instructions advise consulting a healthcare professional or pharmacist for the proper method for discarding any unused or expired Mirapex PD tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Мирапекс ПД found in:

A-Z Index: